Lupin obtains tentative OK for generic QternDapagliflozin and Saxagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus. Amneal touts 39 retail, injectable product launches in 2023In the fourth quarter of 2023, Amneal launched 13 new products, including 5 injectables. Alembic intros generic Enablex Darifenacin ER Tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Web app for biosimilars education debuts The app provides resources for engaging patients when switching to a biosimilar and understanding managed care requirements. Lupin receives FDA nod for 3 generics The FDA has approved Lupin's generic Alrex, generic Zyloprim and generic Januvia. Natco Pharma completes transition of DASH Pharmaceuticals into Natco Pharma USA As of Jan. 2, all products marketed by the company will transition to the Natco Pharma USA label, with no changes to the current NDC numbers. Endo files reorganization plan to emerge from bankruptcy The plan paves the way for Endo to successfully conclude financial restructuring in the second quarter of 2024. Teva intros generic Forteo Generic Forteo is used to treat men and women with certain types of osteoporosis. Hikma intros phenylephrine HCl Injection Phenylephrine HCl Injection is indicated for increasing blood pressure in adults with hypotension resulting primarily from vasodilation in the setting of anesthesia. Amneal moves to Nasdaq The Nasdaq move will be effective on Dec. 27, 2023. First Previous 46 47 48 49 50 Next Last
